![]() ![]() (North Chicago, IL, USA) and grants and personal fees from Vifor (International) AG (St Gallen, Switzerland) outside the submitted work. Mathew Brookes reports grants and personal fees from Tillotts Pharma (Lincoln, UK), personal fees from AbbVie Inc. (San Diego, CA, USA) and personal fees and other (travel expenses) from Bristol-Myers Squibb (New York, NY, USA) outside the submitted work. Andrew Beggs reports grants, personal fees and non-financial support from Illumina Inc. Although the test showed an increased number of patients with neoplasia associated with primary methylation changes, this failed to reach statistical significance (diagnostic odds ratio 3.93 95% confidence interval 0.82 to 24.75 p = 0.09).ĭeclared competing interests of authors: Ashish Awasthi reports sponsorship to attend the European Crohn’s and Colitis Organisation’s meeting from Vifor Pharma UK Ltd (Bagshot, UK) and sponsorship to attend British Society of Gastroenterology’s meetings from Norgine Ltd (Uxbridge, UK) outside the submitted work. To determine added value above colonoscopy alone, a second (reference) colonoscopy was performed in 193 patients without neoplasia. The probability of dysplasia increased from 11.1% before testing to 17.7% after testing (95% confidence interval 13.0% to 23.2%), with a positive methylation result suggesting added value in neoplasia detection. The methylation assay (testing non-neoplastic mucosa) was compared with pathology assessments for neoplasia and showed a diagnostic odds ratio of 2.37 (95% confidence interval 1.46 to 3.82 p = 0.0002). ![]() In module 3, 818 patients underwent a baseline colonoscopy. Module 2 was unable to develop a robust next-generation sequencing assay because of the low amplification rates across all genes. Background mucosa had poorer discrimination (optimism-adjusted area under the receiver operating characteristic curve was 0.68, 95% confidence interval 0.62 to 0.73). ![]() Precancerous neoplasia showed a higher area under the receiver operating characteristic curve of 0.88 (95% confidence interval 0.84 to 0.92). The optimism-adjusted area under the receiver operating characteristic curve for neoplasia was 0.83 (95% confidence interval 0.79 to 0.88). Module 1 selected five genes with specificity for neoplasia. Author InformationĪuthors Ashish Awasthi, 1 Jamie Barbour, 2 Andrew Beggs, 3 Pradeep Bhandari, 4 Daniel Blakeway, 3 Matthew Brookes, 5 James Brown, 6 Matthew Brown, 7 Germaine Caldwell, 3 Samuel Clokie, 8 Ben Colleypriest, 9 Abby Conlin, 10 Shanika de Silva, 11 John de Caestecker, 12 Jonathan Deeks, 6,13 Anjan Dhar, 14 Mark Dilworth, 3 Edward Fogden, 15 Stephen Foley, 16 Deb Ghosh, 17 Leonie Grellier, 18 Ailsa Hart, 19 Syed Samiul Hoque, 20 Marietta Iacucci, 21 Tariq Iqbal, 3,21 Jonathan James, 3 Mark Jarvis, 22 Anthoor Jayaprakash, 23 Satish Keshav, 24 Laura Magill, 6 Glenn Matthews, 3 Joel Mawdsley, 25 Simon McLaughlin, 26 Samir Mehta, 6 Kevin Monahan, 25 Dion Morton, 3,21 ,* Senthil Murugesan, 27 Miles Parkes, 28 Valerie Pestinger, 3 Chris Probert, 29 Arvind Ramadas, 30 Alessandro Rettino, 8 Shaji Sebastian, 31 Naveen Sharma, 21,32 Michael Griffiths, 8 Joanne Stockton, 3 Venkat Subramanian, 33 Nigel Suggett, 21 Philippe Taniere, 21 Julian Teare, 34 Ajay M Verma, 35 and Yvonne Wallis 8 on behalf of the ENDCaP-C Collaborative Group. 8.1Īshish Awasthi, Jamie Barbour, Andrew Beggs, Pradeep Bhandari, Daniel Blakeway, Matthew Brookes, James Brown, Matthew Brown, Germaine Caldwell, Samuel Clokie, Ben Colleypriest, Abby Conlin, Shanika de Silva, John de Caestecker, Jonathan Deeks, Anjan Dhar, Mark Dilworth, Edward Fogden, Stephen Foley, Deb Ghosh, Leonie Grellier, Ailsa Hart, Syed Samiul Hoque, Marietta Iacucci, Tariq Iqbal, Jonathan James, Mark Jarvis, Anthoor Jayaprakash, Satish Keshav, Laura Magill, Glenn Matthews, Joel Mawdsley, Simon McLaughlin, Samir Mehta, Kevin Monahan, Dion Morton, Senthil Murugesan, Miles Parkes, Valerie Pestinger, Chris Probert, Arvind Ramadas, Alessandro Rettino, Shaji Sebastian, Naveen Sharma, Michael Griffiths, Joanne Stockton, Venkat Subramanian, Nigel Suggett, Philippe Taniere, Julian Teare, Ajay M Verma, and Yvonne Wallis on behalf of the ENDCaP-C Collaborative Group. Enhanced neoplasia detection in chronic ulcerative colitis: the ENDCaP-C diagnostic accuracy studyĮfficacy and Mechanism Evaluation, No. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |